Regeneron Pharmaceuticals Overview
Regeneron Pharmaceuticals Target Price
Analysts' 12-month price predictions for REGN.
Share Price
$483.07
Average Target Price
$816.00
68.9% upside
68.9% upside3 analysts in the last 4 months
High: $903 | Low: $695
Analyst Recommendations
No recommendations in the last 4 months.
Revenue & Income Forecast
Analysts' Target Prices
| Date | Analyst | Price Target | Current Upside/Downside | |
|---|---|---|---|---|
| 2025-04-22 | Cantor FitzgeraldCarter Gould | $695 | 43.9% upside |  |
| 2025-04-22 | Canaccord GenuityJohn Newman | $850 | 76% upside | |
| 2025-03-14 | BMO Capital | $903 | 86.9% upside | |
| 2024-11-01 | Leerink PartnersAndrew Berens | $880 | 82.2% upside | |
| 2024-11-01 | BMO CapitalEvan David Seigerman | $1,190 | 146.3% upside | |
| 2024-11-01 | Piper SandlerChristopher Raymond | $1,195 | 147.4% upside | |
| 2024-10-31 | Evercore ISICory Kasimov | $1,170 | 142.2% upside | |
| 2024-10-24 | Evercore ISICory Kasimov | $1,175 | 143.2% upside | |
| 2024-10-23 | Wells FargoMohit Bansal | $1,050 | 117.4% upside | |
| 2024-09-24 | Goldman SachsSalveen Richter | $1,292 | 167.5% upside | |
| 2024-09-24 | Truist FinancialThomas Klee | $1,200 | 148.4% upside | |
| 2024-09-24 | Leerink PartnersDavid Risinger | $1,077 | 122.9% upside | |
| 2024-09-24 | Robert W. BairdBrian Skorney | $940 | 94.6% upside | |
| 2024-09-12 | BMO CapitalEvan David Seigerman | $1,300 | 169.1% upside | |
| 2024-09-09 | RBC CapitalBrian Abrahams | $1,282 | 165.4% upside | |
| 2024-08-23 | Raymond JamesChristopher Raymond | $1,242 | 157.1% upside | |
| 2024-08-02 | RBC CapitalBrian Abrahams | $1,240 | 156.7% upside | |
| 2024-08-02 | Bank of America SecuritiesGeoff Meacham | $805 | 66.6% upside | |
| 2024-07-19 | Raymond JamesChristopher Raymond | $1,166 | 141.4% upside | |
| 2024-07-18 | GuggenheimYatin Suneja | $1,180 | 144.3% upside | |
| 2024-07-12 | UBSTrung Huynh | $1,250 | 158.8% upside | |
| 2024-07-11 | Morgan StanleyTerence Flynn | $1,182 | 144.7% upside | |
| 2024-06-25 | Argus ResearchJasper Hellweg | $1,170 | 142.2% upside | |
| 2024-06-13 | RBC CapitalBrian Abrahams | $1,299 | 168.9% upside | |
| 2024-06-12 | RBC CapitalBrian Abrahams | $1,229 | 154.4% upside | |
| 2024-06-04 | RBC CapitalBrian Abrahams | $1,200 | 148.4% upside | |
| 2024-06-03 | BMO CapitalEvan David Seigerman | $1,082 | 124% upside | |
| 2024-05-20 | Raymond JamesChristopher Raymond | $1,000 | 107% upside | |
| 2024-05-13 | Evercore ISICory Kasimov | $1,150 | 138.1% upside | |
| 2024-05-03 | RBC CapitalBrian Abrahams | $1,185 | 145.3% upside | |
| 2024-04-12 | JefferiesAkash Tewari | $1,060 | 119.4% upside | |
| 2024-04-11 | RBC CapitalBrian Abrahams | $1,189 | 146.1% upside | |
| 2024-03-13 | Morgan StanleyMatthew Harrison | $1,115 | 130.8% upside | |
| 2024-01-12 | BMO CapitalBrian Abrahams | $1,076 | 122.7% upside | |
| 2024-01-12 | RBC CapitalBrian Abrahams | $1,076 | 122.7% upside | |
| 2023-03-27 | Leerink PartnersAndrew Berens | $976 | 102% upside | |
| 2023-03-24 | JefferiesAkash Tewari | $925 | 91.5% upside | |
| 2023-02-08 | EF Hutton | $853 | 76.6% upside | |
| 2023-02-06 | Leerink Partners | $834 | 72.6% upside | |
| 2023-02-06 | RBC Capital | $787 | 62.9% upside | |
| 2023-02-06 | Morgan Stanley | $883 | 82.8% upside | |
| 2022-11-11 | Guggenheim | $915 | 89.4% upside | |
| 2022-10-03 | Goldman Sachs | $970 | 100.8% upside | |
| 2022-09-16 | Canaccord Genuity | $750 | 55.3% upside | |
| 2022-09-13 | Piper Sandler | $775 | 60.4% upside | |
| 2022-09-12 | Wells Fargo | $800 | 65.6% upside | |
| 2022-09-09 | Barclays | $815 | 68.7% upside | |
| 2022-09-09 | Morgan StanleyMatthew Harrison | $851 | 76.2% upside | |
| 2022-09-08 | JefferiesAkash Tewari | $675 | 39.7% upside | |
| 2022-08-15 | Morgan StanleyMatthew Harrison | $625 | 29.4% upside | |